Tech Company Financing Transactions
Alzheon Funding Round
Alzheon, based in Framingham, received $10 million in funding from Ally Bridge Group and private investors.
Transaction Overview
Company Name
Announced On
4/8/2015
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Ally Bridge Group (Lead Investor)
Proceeds Purpose
Proceeds of the financing will be used to advance Alzheon's lead drug candidate, ALZ-801, an oral, small molecule, first-in-class inhibitor of amyloid formation and neurotoxicity, toward completion of the clinical and regulatory studies for initiation of a potential pivotal clinical study in Alzheimer's disease in the near future.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
111 Speen St. 306
Framingham, MA 01701
USA
Framingham, MA 01701
USA
Phone
Website
Email Address
Not Recorded
Overview
Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Tolar
Chief Medical Officer
Susan Abushakra
Chief Scientific Officer
John Hey
Vice President
Aidan Power
VP - Finance
Kenneth Mace
Browse more venture capital transactions:
Prev: 4/8/2015: Amberjack venture capital transaction
Next: 4/8/2015: Lens Vector venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs